Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03423342
Other study ID # STUDY00001830
Secondary ID 1R21HL126209-01
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date May 19, 2016
Est. completion date June 30, 2019

Study information

Verified date October 2022
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide (NAD), or the NADH/NAD ratio. In mouse models of HF, we have found that normalization of the NADH/NAD, through supplementation with NAD+ precursors, is associated with improvement in cardiac function. This Study will randomize participants with systolic HF (ejection fraction ≤40%) to treatment with the NAD precursor, nicotinamide riboside (NR) or matching placebo, uptitrated to a final oral dose of 1000mg twice daily, to determine the safety and tolerability of NR in participants with systolic HF.


Description:

Aim 1: Determine the safety and tolerability of NR in patients with clinically stable, systolic heart failure (LVEF <40%). To accomplish this Aim: A) a total of 30 participants with clinically stable, systolic heart failure (LVEF <40%) will undergo 2:1 randomization to NR 250mg PO twice daily or matching placebo B) NR (or matching placebo), will be increased weekly by 250mg/dose (500mg/day) to a final dose of 1000mg PO twice daily. Clinic visits with labs bi-weekly during dose escalation will assess HF symptoms and monitor labs [B-type natriuretic peptide (BNP), complete blood count (CBC), glycosylated hemoglobin, alanine aminotransferase (ALT), creatine kinase (CK), insulin/glucose, uric acid, electrolytes, blood urea nitrogen (BUN) and creatinine (Cr). C) to ensure intermediate-term safety and tolerability, participants will continue on their maximum tolerated dose (of NR or placebo) through Study Week 12 Aim 2: Determine whether, at the doses employed, NR and NAD are detectable in whole blood. Aim 3 (Exploratory): Assess the range of potential effect sizes of NR on HF surrogate endpoints using: A) Six-minute walk tests (6MWTs) at each visit (including Screening) to assess functional capacity B) Echocardiography at Baseline and Week 12 to assess LV systolic function (by real-time, 3D echocardiography) and diastolic function (by integrated Doppler and tissue Doppler imaging)


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date June 30, 2019
Est. primary completion date April 11, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women aged 18 and older with systolic heart failure [left ventricular ejection fraction (LVEF) by standard 2D echocardiography or radionuclide ventriculography of =40%] deemed, in the clinical opinion of their treating cardiologist to be non-ischemic or ischemic in origin. - Clinically stable (no cardiac procedures or hospitalizations for hospitalizations for cardiac causes, including HF, ischemia or arrhythmia) within the previous 3 months - Ability to undergo study procedures, including scheduled visits, blood draws and six-minute walk test (6MWT) - Willingness/ability to provide informed consent Exclusion Criteria: - Heart failure with preserved ejection fraction (LVEF greater than 40%) - Heart failure due, in the opinion of their treating cardiologist, to etiologies other than non-ischemic or ischemic. Examples of exclusionary heart failure etiologies include primary valvular disease, or infiltrative or inflammatory cardiomyopathies. - Cardiac surgery, percutaneous coronary intervention (PCI) or cardiac device implantation within the previous 3 months - Hospitalizations for cardiovascular causes, including heart failure, chest pain, stroke, transient ischemic attack or arrhythmias within the previous 3 months - Inability to perform Study visits or procedures (e.g., physical inability to perform 6MWT) - Unwillingness/inability to provide informed consent - ALT greater than 3 times the upper limit of normal, hepatic insufficiency or active liver disease - Recent history of acute gout - Chronic renal insufficiency with creatinine =2.5mg/dL - Pregnant (or likely to become pregnant) women - Significant co-morbidity likely to cause death in the 6 month follow-up period - Significant active history of substance abuse within the previous 5 years - Current participation in another long-term clinical trial - History of intolerance to NR precursor compounds, including niacin or nicotinamide

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
nicotinamide riboside
nicotinamide riboside capsule
Drug:
Placebo
matching placebo capsule

Locations

Country Name City State
United States University of Washington Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Washington National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory Endpoint: Effect of NR on Functional Capacity Change in Six Minute Walk Distance Week 12 - Week 0
Other Exploratory Endpoint: Effect of NR on Change in Left Ventricular Systolic Function Change in Left Ventricular Ejection Fraction by 3D-Transthoracic Echocardiography Week 12 - Week 0
Other Exploratory Endpoint: Effect of NR on Left Ventricular Diastolic Function Tissue Doppler Imaging, e' Week 12 - Week 0
Primary Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) Adverse Events up to 12 weeks
Secondary On-Trial Change in Whole Blood NAD+ Levels Between-group comparison of On-Trial Change in Whole Blood NAD+ Levels Week 12-Week 0
Secondary Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment Incidence of On-Trial Abnormal Laboratory Values and/or Adverse Events that Are Related to Treatment 16 weeks
Secondary Effect of NR on Change in Mitochondrial Function (Maximal Oxygen Consumption Rate) Mitochondrial Respiration in Isolated Peripheral Blood Mononuclear Cells by the Seahorse (R) Assay Week 12 - Week 0
See also
  Status Clinical Trial Phase
Withdrawn NCT03227393 - The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG N/A
Recruiting NCT04528004 - Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure Early Phase 1
Recruiting NCT04703842 - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction Phase 1/Phase 2
Recruiting NCT04522609 - Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant N/A
Completed NCT05475028 - Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Not yet recruiting NCT06240403 - Digoxin and Senolysis in Heart Failure and Diabetes Mellitus Phase 2
Not yet recruiting NCT05988749 - Digital Remote Home Monitoring for Heart Failure N/A
Recruiting NCT04950218 - The Psoriasis Echo Study
Suspended NCT04701112 - Acute Hemodynamic Effects of Pacing the His Bundle in Heart Failure N/A
Completed NCT03305692 - ECG Belt vs. Echocardiographic Optimization of CRT N/A
Recruiting NCT05933083 - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation N/A
Enrolling by invitation NCT03903107 - The Fluoroless-CSP Trial Using Electroanatomic Mapping N/A
Withdrawn NCT04872959 - TRANSFORM Heart Failure With Reduced Ejection Fraction N/A
Completed NCT02920918 - Treatment of Diabetes in Patients With Systolic Heart Failure Phase 4
Completed NCT02334891 - Kyoto Congestive Heart Failure Study
Recruiting NCT03553303 - Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin Phase 4
Recruiting NCT04083690 - Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Recruiting NCT06121323 - Physiological Effects of Lactate in Individuals With Chronic Heart Failure N/A
Completed NCT03351283 - Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure N/A